Abstract
Health care workers (HCW) are exposed to ribavirin aerosol during therapy of infants with respiratory syncytial virus infections. To assess the degree of HCW exposure, we analyzed air samples from patient rooms and HCW personal breathing zones during ribavirin aerosol delivery by ventilator (two samples), oxygen hood (two samples), and a new vacuum exhaust hood (four samples). HCW exposure to ribavirin during aerosol delivery by ventilator or vacuum exhaust hood system was substantially lower than HCW exposure during aerosol delivery by oxygen hood in rooms with adequate ventilation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Austin R. K., Trefts P. E., Hintz M., Connor J. D., Kagnoff M. F. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob Agents Chemother. 1983 Nov;24(5):696–701. doi: 10.1128/aac.24.5.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Conrad D. A., Christenson J. C., Waner J. L., Marks M. I. Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr Infect Dis J. 1987 Feb;6(2):152–158. doi: 10.1097/00006454-198702000-00003. [DOI] [PubMed] [Google Scholar]
- Hall C. B., McBride J. T., Gala C. L., Hildreth S. W., Schnabel K. C. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985 Dec 6;254(21):3047–3051. [PubMed] [Google Scholar]
- Hall C. B., McBride J. T., Walsh E. E., Bell D. M., Gala C. L., Hildreth S., Ten Eyck L. G., Hall W. J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983 Jun 16;308(24):1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
- Hall C. B., McBride J. T., Walsh E. E., Bell D. M., Gala C. L., Hildreth S., Ten Eyck L. G., Hall W. J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983 Jun 16;308(24):1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
- Johnson E. M. Cross-species extrapolations and the biologic basis for safety factor determinations in developmental toxicology. Regul Toxicol Pharmacol. 1988 Mar;8(1):22–36. doi: 10.1016/0273-2300(88)90004-9. [DOI] [PubMed] [Google Scholar]
- Rodriguez W. J., Bui R. H., Connor J. D., Kim H. W., Brandt C. D., Parrott R. H., Burch B., Mace J. Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrob Agents Chemother. 1987 Jul;31(7):1143–1146. doi: 10.1128/aac.31.7.1143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rodriguez W. J., Kim H. W., Brandt C. D., Fink R. J., Getson P. R., Arrobio J., Murphy T. M., McCarthy V., Parrott R. H. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J. 1987 Feb;6(2):159–163. doi: 10.1097/00006454-198702000-00004. [DOI] [PubMed] [Google Scholar]
- Taber L. H., Knight V., Gilbert B. E., McClung H. W., Wilson S. Z., Norton H. J., Thurson J. M., Gordon W. H., Atmar R. L., Schlaudt W. R. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983 Nov;72(5):613–618. [PubMed] [Google Scholar]